Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Jung Hyun Her"'
Autor:
Young Bae Choi, Meong Hi Son, Hee Won Cho, Youngeun Ma, Ji Won Lee, Eun-Suk Kang, Keon Hee Yoo, Jung Hyun Her, Okjae Lim, Miyoung Jung, Yu Kyeong Hwang, Ki Woong Sung, Hong Hoe Koo
Publikováno v:
PLoS ONE, Vol 14, Iss 12, p e0225998 (2019)
INTRODUCTION:Under the hypothesis that early natural killer cell infusion (NKI) following haploidentical stem cell transplantation (haplo-SCT) will reduce relapse in the early post-transplant period, we conducted a pilot study to evaluate the safety
Externí odkaz:
https://doaj.org/article/ed9be5a73a1249518dc7933ca54193de
Autor:
Okjae Lim, Yuna Lee, Hyejin Chung, Jung Hyun Her, Sang Mi Kang, Mi-young Jung, Bokyung Min, Hyejin Shin, Tae Min Kim, Dae Seog Heo, Yu Kyeong Hwang, Eui-Cheol Shin
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e53611 (2013)
Ex vivo-expanded, allogeneic natural killer (NK) cells can be used for the treatment of various types of cancer. In allogeneic NK cell therapy, NK cells from healthy donors must be expanded in order to obtain a sufficient number of highly purified, a
Externí odkaz:
https://doaj.org/article/9903fe351f864473b8f365b4c69c9dce
Autor:
Dae Seog Heo, Yu Kyeong Hwang, Dong-Wan Kim, Se-Hoon Lee, Bhumsuk Keam, Sung Yoo Cho, Jung Hyun Her, Bokyung Min, Hyejin Chung, Hana Choi, Yong-Oon Ahn, Tae Min Kim, Okjae Lim, Yaewon Yang
Supplementary Table S1. Demographic characteristics; Supplementary Table S2. Post-transfusion kinetics of donor NK cells in recipient peripheral blood
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e441c3b97854296ab5328a99934de1d
https://doi.org/10.1158/2326-6066.22538485
https://doi.org/10.1158/2326-6066.22538485
Autor:
Dae Seog Heo, Yu Kyeong Hwang, Dong-Wan Kim, Se-Hoon Lee, Bhumsuk Keam, Sung Yoo Cho, Jung Hyun Her, Bokyung Min, Hyejin Chung, Hana Choi, Yong-Oon Ahn, Tae Min Kim, Okjae Lim, Yaewon Yang
Natural killer (NK) cells with mismatched killer cell immunoglobulin-like receptor–ligand pairs have shown efficacy and been proven safe in treatment of cancer patients. Ex vivo–expanded and highly activated NK cells (MG4101) had been generated u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::539a4f3f0aab1e7fdf6ff6e321c5da89
https://doi.org/10.1158/2326-6066.c.6548794.v1
https://doi.org/10.1158/2326-6066.c.6548794.v1
Autor:
Dae Seog Heo, Yu Kyeong Hwang, Dong-Wan Kim, Se-Hoon Lee, Bhumsuk Keam, Sung Yoo Cho, Jung Hyun Her, Bokyung Min, Hyejin Chung, Hana Choi, Yong-Oon Ahn, Tae Min Kim, Okjae Lim, Yaewon Yang
Supplementary Figure S1. Clinical treatment protocol; Supplementary Figure S2. Characterization of ex vivo-expanded NK cells; Supplementary Figure S3. Analysis of donor KIR genotype and clinical outcome; Supplementary Figure S4. Kinetics of donor NK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3709b5a57732a909bde26cae732ddb43
https://doi.org/10.1158/2326-6066.22538488.v1
https://doi.org/10.1158/2326-6066.22538488.v1
Autor:
Jung Hyun Her, Dominik Pretscher, Maria Patra-Kneuer, Juergen Schanzer, Sung Yoo Cho, Yu Kyeong Hwang, Timm Hoeres, Rainer Boxhammer, Christina Heitmueller, Martin Wilhelm, Stefan Steidl, Jan Endell
Publikováno v:
Cancer Immunology, Immunotherapy. 71:2829-2836
Tafasitamab is an Fc-modified monoclonal antibody that binds to CD19, a cell-surface antigen that is broadly expressed on various types of B-cell non-Hodgkin’s lymphoma (NHL). Antibody-dependent cellular cytotoxicity (ADCC), a key mode of action of
Autor:
Jae-Won Joh, Jung Hyun Her, Gyu-Seong Choi, Jong Man Kim, Miyoung Jung, Sung Yoo Cho, Eui-Cheol Shin, Yu-Kyeong Hwang, Jinsoo Rhu, Okjae Lim
Publikováno v:
Annals of Hepato-Biliary-Pancreatic Surgery
Backgrounds/aims Fewer reports have been published regarding hepatectomy patients with solitary hepatocellular carcinoma (HCC) who received immunotherapeutic agents as adjuvant therapy. We evaluated the safety and efficacy of ex vivo-expanded allogen
Autor:
Keon Hee Yoo, Ji Won Lee, Jung Hyun Her, Youngeun Ma, Hee Won Cho, Young Bae Choi, Hong Hoe Koo, Miyoung Jung, Okjae Lim, Ki Woong Sung, Meong Hi Son, Eun-Suk Kang, Yu Kyeong Hwang
Publikováno v:
PLoS ONE, Vol 14, Iss 12, p e0225998 (2019)
PLoS ONE
PLoS ONE
Introduction Under the hypothesis that early natural killer cell infusion (NKI) following haploidentical stem cell transplantation (haplo-SCT) will reduce relapse in the early post-transplant period, we conducted a pilot study to evaluate the safety
Autor:
Sung Yoo Cho, Yong Oon Ahn, Bhumsuk Keam, Okjae Lim, Dong Wan Kim, Dae Seog Heo, Yu Kyeong Hwang, Jung Hyun Her, Tae Min Kim, Hyejin Chung, Yaewon Yang, Hana Choi, Bokyung Min, Se-Hoon Lee
Publikováno v:
Cancer Immunology Research. 4:215-224
Natural killer (NK) cells with mismatched killer cell immunoglobulin-like receptor–ligand pairs have shown efficacy and been proven safe in treatment of cancer patients. Ex vivo–expanded and highly activated NK cells (MG4101) had been generated u
Autor:
Dominik Pretscher, Jung Hyun Her, Rainer Boxhammer, Juergen Schanzer, Stefan Steidl, Timm Hoeres, Yu-Kyeong Hwang, Jan Endell, Sungyoo Cho, Maria Patra
Publikováno v:
Blood. 134:3801-3801
Introduction Tafasitamab (MOR208) is an Fc-enhanced, humanized, monoclonal antibody that binds to the human B cell surface antigen CD19. CD19 is broadly and homogeneously expressed across different B cell malignancies, including diffuse large B cell